Please Wait
Applying Filters...
menu
    • menu

    Annual Sales of Carfilzomib reported using PharmaCompass' compilation of Annual Reports of Global Pharmaceutical Companies.

    Client Email Product
    Renejix: CDMO with expertise in small molecule oral dosage, delivery tech, and multi-modality manufacturing.

    Virtual Booth

    Contact Supplier

    SPI Pharma has been solving formulation challenges using superior functional materials.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Ribobay has expertise in oligonucleotides from siRNA, Antisense Oligonucleotides, miRNAs, and aptamers & Oligonucleotides CXOs.

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    xyz-pharma-m-2024-10-07

    Virtual Booth

    Contact Supplier

    Menu

    Carfilzomib

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PRICE INFORMATION

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    EXCIPIENTS BY APPLICATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 379,820Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 18Kyprolis

    02 1Vidaza

    PharmaCompass
    Left Arrow
    Right Arrow
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 1,065

    2019 Revenue in Millions : 1,044

    Growth (%) : 2

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Ono Pharma

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2020 Revenue in Millions : 65

    2019 Revenue in Millions : 53

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 1,108

    2020 Revenue in Millions : 1,065

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Ono Pharma

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2021 Revenue in Millions : 69

    2020 Revenue in Millions : 62

    Growth (%) : 21

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    China
    arrow
    AAPS 2024
    Not Confirmed

    BeiGene

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 14

    2021 Revenue in Millions : 0

    Growth (%) : New Launch in 2022

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Ono Pharmaceuticals

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 67

    2021 Revenue in Millions : 69

    Growth (%) : -3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2022 Revenue in Millions : 1,247

    2021 Revenue in Millions : 1,108

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    U.S.A
    arrow
    AAPS 2024
    Not Confirmed

    Amgen

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 1,403

    2022 Revenue in Millions : 1,247

    Growth (%) : 13

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Vidaza

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Vidaza

    China
    arrow
    AAPS 2024
    Not Confirmed

    BeiGene

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 43

    2022 Revenue in Millions : 14

    Growth (%) : 191

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Kyprolis

    Carfilzomib

    arrow
    AAPS 2024
    Not Confirmed

    Brand Name : Kyprolis

    Japan
    arrow
    AAPS 2024
    Not Confirmed

    Ono Pharmaceuticals

    Carfilzomib

    Main Therapeutic Indication : Oncology

    Currency : USD

    2023 Revenue in Millions : 61

    2022 Revenue in Millions : 67

    Growth (%) : 3

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF